Thus, blockade of RAS, including the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB), can effectively suppress the progression of kidney diseases in both animal experiments and large-scale clinical studies. Here, ACE is linked to kidney disorder.